Track topics on Twitter Track topics that are important to you
Novartis, alongside Medicines for Malaria Venture (MMV), have revealed that trials into a new antimalarial compound have begun in a first clinic in Mali. The trial is investigating a compound, KAF156, as a potentially ground-breaking treatment that can clear malaria infection, including particularly resistant strains, and block the transmission of the malaria parasite.
Original Article: Novartis begins ‘next-generation’ malaria treatment trialNEXT ARTICLE
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...
Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...